Vahanian Nicholas N. 4

Accession 0001126234-19-000100

CIK 0001126234other

View on SEC.gov Company Profile

Filed

Aug 1, 8:00 PM ET

Accepted

Aug 2, 6:37 PM ET

Size

54.8 KB

Accession

0001126234-19-000100

Insider Transaction Report

Form 4

Period: 2019-07-31

NEWLINK GENETICS CORP(NLNK)

Vahanian Nicholas N.

Pres, Chief Medical Officer

Transactions

Award
Stock Option (Right to Buy)
2019-07-31+439→ 439 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (439 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+22,580→ 22,580 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (22,580 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−42,857→ 0 total
Exercise: $7.00From: 2012-04-14Exp: 2021-11-09→ Common Stock (42,857 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+7,143→ 7,143 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (7,143 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−380,952→ 0 total
Exercise: $2.97From: 2010-12-04Exp: 2019-12-03→ Common Stock (380,952 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+167,896→ 167,896 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (167,896 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+95,238→ 95,238 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (95,238 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+31,921→ 31,921 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (31,921 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−90,000→ 0 total
Exercise: $11.79From: 2014-01-14Exp: 2023-01-13→ Common Stock (90,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−71,250→ 0 total
Exercise: $21.38Exp: 2024-01-01→ Common Stock (71,250 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+19,438→ 19,438 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (19,438 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−84,275→ 0 total
Exercise: $34.73Exp: 2026-01-03→ Common Stock (84,275 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−190,476→ 0 total
Exercise: $3.07From: 2010-12-04Exp: 2020-03-02→ Common Stock (190,476 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+14,286→ 14,286 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (14,286 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−80,000→ 0 total
Exercise: $6.87From: 2013-01-18Exp: 2022-01-18→ Common Stock (80,000 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+8,080→ 8,080 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (8,080 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+26,872→ 26,872 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (26,872 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+3,129→ 3,129 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (3,129 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+22,041→ 22,041 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (22,041 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+813→ 813 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (813 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+190→ 190 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (190 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+1,710→ 1,710 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (1,710 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2019-07-31−81,000→ 0 total
Exercise: $43.65Exp: 2025-01-01→ Common Stock (81,000 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+18,246→ 18,246 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (18,246 underlying)
Award
Stock Option (Right to Buy)
2019-07-31+2,195→ 2,195 total
Exercise: $1.77Exp: 2026-07-31→ Common Stock (2,195 underlying)

Footnotes (6)

[F1]On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.
[F2]The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date.
[F3]On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every three cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.
[F4]The option provided that it would vest in 48 equal monthly installments beginning the first month after grant date subject to the Reporting Person's continuous service as of such date.
[F5]On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every four cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share.
[F6]The option vests as to 50% on the second anniversary of grant date and the remaining 50% on the third anniversary of grant date.

Documents

1 file

4
wf-form4_156478545394047.xmlPrimary
FORM 4

Issuer

NEWLINK GENETICS CORP

CIK 0001126234

→

Entity typeother

Related Parties

filerCIK 0001512114

Filing Metadata

Form type: 4
Filed: Aug 1, 8:00 PM ET
Accepted: Aug 2, 6:37 PM ET
Size: 54.8 KB

View on SEC.gov